CIK 0001880438
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
AN2 Therapeutics, Inc.
Sign in to watch- Ticker
- ANTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 820606654
- Phone
- +1 650-331-9090
- Business address
- 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 11,560 shares (grant or award)
- 4 Grant or award Director acquired 3,650 shares (grant or award)
- 4 Grant or award Director acquired 11,560 shares (grant or award)
- 4 Open-market sale Chief Financial Officer sold 8,807 shares at an average $1.01 ($8,883)
- 4 Open-market sale Chief Strategy Officer sold 6,462 shares at an average $1.01 ($6,507)
- 4 Open-market sale Chief Development Officer sold 9,251 shares at an average $1.01 ($9,332)
- 4 Open-market sale Eizen Joshua M sold 24,854 shares at an average $1.00 ($24,962)
- 4 Open-market sale Eizen Joshua M sold 2,819 shares at $1.14 ($3,214)
- 4 Open-market sale Chief Strategy Officer sold 765 shares at $1.14 ($872)
- 4 Grant or award Director acquired 10,367 shares (grant or award)
- 4 Grant or award Director acquired 10,367 shares (grant or award)
- 4 Grant or award Director acquired 3,274 shares (grant or award)
- 4 Grant or award Director acquired 11,875 shares (grant or award)
Page 3 of 11 · 216 filings